Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05829226 | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 101 | PureTechINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY |
| 4 |
| May 6, 2026 |
| clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07093073 | Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma | recruiting | Phase 1 | 30 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07093086 | Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07453446 | Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma | withdrawn | Phase 1 | 0 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05400109 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | active not recruiting | Phase 1 | 21 | David WaldOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | recruiting | Phase 1 | 30 | David AviganOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT00641381 | Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | active not recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | recruiting | Phase 1 / Phase 2 | 180 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | active not recruiting | Phase 1 | 74 | Ascentage Pharma Group Inc.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT04167917 | NTX-301 in MDS/AML | completed | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283679 | Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07551037 | Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy(AML) | recruiting | Phase 1 | 90 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02993146 | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05347225 | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | active not recruiting | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04819854 | Single and Multiple Ascending Dose Study With EP395 | completed | Phase 1 | 78 | EpiEndo PharmaceuticalsINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02211755 | Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02315612 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | completed | Phase 1 | 134 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02732275 | DS-3201b in Participants With Lymphomas | active not recruiting | Phase 1 | 100 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02783625 | Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas | completed | Phase 1 | 114 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma(MM) | active not recruiting | Phase 1 | 275 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05101551 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy(PARPAML) | recruiting | Phase 1 | 34 | Norman J. LacayoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07320235 | Imetelstat Combinations in Relapsed AML(IMAGINE) | recruiting | Phase 1 | 36 | Douglas TremblayOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01853358 | Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation(DLI-NK) | completed | Phase 1 | 17 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | CelgeneINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 6, 2026source: clinicaltrials